Literature DB >> 10496802

The third generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills.

P A O'Brien.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10496802      PMCID： PMC1116644          DOI： 10.1136/bmj.319.7213.795

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95.

Authors:  L Mellemkjaer; H T Sørensen; L Dreyer; J Olsen; J H Olsen
Journal:  BMJ       Date:  1999-09-25

2.  Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

3.  The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.

Authors:  M A Lewis; L A Heinemann; W O Spitzer; K D MacRae; R Bruppacher
Journal:  Contraception       Date:  1997-09       Impact factor: 3.375

Review 4.  Newer oral contraceptives and the risk of venous thromboembolism.

Authors:  A M Walker
Journal:  Contraception       Date:  1998-03       Impact factor: 3.375

5.  Venous thromboembolism among new users of different oral contraceptives.

Authors:  R M Herings; J Urquhart; H G Leufkens
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

6.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

Authors:  K W Bloemenkamp; F R Rosendaal; F M Helmerhorst; H R Büller; J P Vandenbroucke
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

7.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

8.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

9.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  W O Spitzer; M A Lewis; L A Heinemann; M Thorogood; K D MacRae
Journal:  BMJ       Date:  1996-01-13

10.  Oral contraceptives and venous thromboembolism. A case-control study.

Authors:  O Lidegaard; B Edström; S Kreiner
Journal:  Contraception       Date:  1998-05       Impact factor: 3.375
View more
  2 in total

1.  Competing interests and controversy about third generation oral contraceptives. BMJ readers should know whose words they read.

Authors:  J P Vandenbroucke; F M Helmerhorst; F R Rosendaal
Journal:  BMJ       Date:  2000-02-05

2.  Symmetrical analysis of risk-benefit.

Authors:  John B Warren; Simon Day; Peter Feldschreiber
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.